Related Experiment Video

Updated: Jun 14, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells

Nancy Y Villa1, Eric Bartee, Mohamed R Mohamed

  • 1Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida 32610, USA.

Virology
|March 26, 2010
PubMed

Insights

Myxoma (MYXV) and vaccinia (VACV) viruses show distinct entry mechanisms into human cancer cells. Understanding these differences in viral entry is key for developing effective oncolytic virotherapy strategies.

Area of Science:

  • Virology
  • Oncology
  • Cell Biology

Background:

  • Myxoma (MYXV) and vaccinia (VACV) viruses are poxviruses with potential as oncolytic agents.
  • Both viruses can infect and induce death in various human cancer cells.
  • Mechanistic similarities in their cancer cell entry pathways remain largely unexplored.

Purpose of the Study:

  • To compare the entry mechanisms of MYXV and VACV-WR into human cancer cells.
  • To elucidate the distinct pathways exploited by these viruses for cancer cell infection.

Main Methods:

  • Comparative analysis of viral entry under different conditions.
  • Assessment of low-pH treatment effects on viral fusion.
  • Evaluation of tyrosine kinase inhibitor (genistein) impact on viral entry.
  • Investigation of PAK1's role in viral entry and post-entry events using knockdown.

Main Results:

  • Low-pH treatment accelerated fusion-mediated entry for VACV but not MYXV.
  • Genistein inhibited VACV entry, while MYXV entry remained unaffected.
  • PAK1 knockdown impaired VACV entry, but affected a later stage post-MYXV entry.

Conclusions:

  • MYXV and VACV utilize fundamentally different mechanisms to enter human cancer cells.
  • These distinct entry pathways may explain the observed differences in their cancer cell tropisms.
  • Findings provide a rationale for differential application of these oncolytic viruses.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Merkel Cell Polyomavirus Infection and Detection13:45

Merkel Cell Polyomavirus Infection and Detection

Published on: February 7, 2019

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...